Studies On The Production Technology Of Tetravalent Influenza Split Vaccine

Vaccination is currently the safest and most effective measure to prevent infectious diseases.Influenza is an acute respiratory infection caused by influenza virus and is one of the major public health problems.WHO began work on recommending strains for influenza vaccines in 1973,and has been published twice a year since 1999(for the northern and southern hemispheres strains).Flu vaccine manufacturers around the world determine the composition of vaccines according to WHO recommendations.Although trivalent influenza vaccines have been used for decades,B type have been popular with two strains: B/Victoria/2/87 and B/Yamagata/16/88.These two lineages are alternated or mixed in a lineage-based fashion,and there is no cross-protection between the two lineage type B viruses.Influenza(quadrivalent)split vaccine add another strain of influenza B virus antigen to another lineage based on the existing trivalent vaccine.The increased influenza virus antigens were all using the WHO recommended vaccine strains,and the total antigen weight was increased from 45 μg/0.5 ml to 60 μg/0.5 ml.The antibody reaction produced by the quadrivalent vaccine in animal tests is the same as that of the trivalent vaccine,so the addition of the antigen does not affect the original type III antigen to induce its corresponding antibody response.Based on the approved production process and quality standards of the original trivalent influenza virus split vaccine,this paper studies the production process of Influenza(quadrivalent)split vaccine to determine the feasibility,safety,effectiveness and stability,laying the experimental foundation for the development of new influenza vaccine.